tecovirimat + lanthanum carbonate

Tecovirimat + lanthanum carbonate refers to the co-administration of two drugs: **tecovirimat** and **lanthanum carbonate**. Tecovirimat is an antiviral medication, primarily indicated for the treatment of smallpox and other orthopoxvirus infections, acting by inhibiting the orthopoxvirus VP37 envelope wrapping protein essential for virus egress. Lanthanum carbonate is a non-calcium, non-aluminum phosphate binder used in the management of hyperphosphatemia in patients with chronic kidney disease; it reduces phosphate absorption by binding to dietary phosphate in the gastrointestinal tract. There is no unique fixed-dose combination product with these two ingredients; the term refers to their concurrent use. Studies demonstrate that co-administration of lanthanum carbonate with tecovirimat increases tecovirimat's systemic exposure (Cmax and AUC), but no new therapeutic indication exists for the fixed combination; close monitoring for tecovirimat-related adverse events is advised when used together.[2][3][1][5]